Hubei Biocause Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 000627.SZ

Hubei Biocause Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2023: USD 148.04 M

Hubei Biocause Pharmaceutical Co., Ltd. EBIT is USD 148.04 M for the year ending December 31, 2023, a 82.45% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Hubei Biocause Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2022 was USD 81.14 M, a -98.38% change year over year.
Hubei Biocause Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2021 was USD 5.01 B, a 1,046.26% change year over year.
Hubei Biocause Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2020 was USD 437.03 M, a -15.13% change year over year.
Hubei Biocause Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2019 was USD 514.93 M, a 35.89% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shenzhen Stock Exchange: 000627.SZ

Hubei Biocause Pharmaceutical Co., Ltd.

CEO	Ms. Wenxia Zhou
IPO Date	Nov. 12, 1996
Location	China
Headquarters	#122 Yangwan Road
Employees	1,765
Sector	Health Care
Industries Pharmaceuticals

Description

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, it is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company exports its products to the United States, the European Union, and internationally. Hubei Biocause Pharmaceutical Co., Ltd. is based in Jingmen, China.

Key trends

Past 5 years